Public-registry site landscape for NCT07702578, a AML study sponsored by TScan Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07702578 (registry record) |
| Sponsor | TScan Therapeutics, Inc. |
| Condition(s) | AML; MDS |
| Phase | PHASE3 |
| Listed sites | 17 |
| Site countries | United States |
At Banner Health - MD Anderson Cancer Center — one of the facilities listed on this trial — 8 other studies are actively recruiting AML patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07702578 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →